02 February 2021: Clinical Research
Comparative Effects of Dexmedetomidine and Midazolam on Dreaming of Patients Undergoing Flexible Bronchoscopy During General AnesthesiaLiang Chen 1BCE* , Jun Zhang 1B* , Wensheng He 1B* , Wei Liu 2ADF*
Med Sci Monit 2021; 27:e929000
BACKGROUND: The aim of this study was to compare the effects of dexmedetomidine versus midazolam on the dreaming of patients undergoing flexible bronchoscopy during general anesthesia.
MATERIAL AND METHODS: Patients undergoing flexible bronchoscopy under general anesthesia were randomly divided into a dexmedetomidine group (Group D, n=40) and a midazolam group (Group M, n=40). In group D, patients received 0.5 μg/kg dexmedetomidine and in group M patients received 0.05 mg/kg midazolam intravenously 10 min prior to induction. After bronchoscopy and recovery, a modified Brice questionnaire was used to immediately evaluate the incidence of dreaming of patients. Dreamers were required to complete a 5-point Likert scale survey regarding the contents of their dreams (emotion, voice and movement, memorability) if dreaming was reported. Ramsay Sedation Scale score (Ramsay score) and Visual Analogue Scale (VAS) score were assessed and recorded.
RESULTS: Patients in group D had higher Ramsay scores and VAS scores (2.9±0.6 and 79.4±4.0, respectively) than group M (2.4±0.7 and 75.0±6.0, respectively), with a statistically significant difference (P<0.05) between groups. The incidence and memorability of dreaming were significantly lower in group D (17.5%) than group M (37.5%, P<0.05), whereas no significant difference was found in emotion, voice, and movement scores of dreaming.
CONCLUSIONS: Compared to midazolam, pre-injection of dexmedetomidine before induction significantly decreased the incidence of dreaming in patients undergoing flexible bronchoscopy during general anesthesia, without producing undesirable effects on the content of dreams (most of them were pleasant), produces a more efficacious sedation effect during the recovery period and improves the comfort level and satisfaction of patients.
Keywords: Anesthesia, General, Bronchoscopy, Dexmedetomidine, Dreams, Midazolam
Flexible bronchoscopy, the most valuable method for direct examination of airway, is commonly performed by physicians . The application of bronchoscopy in patients is limited by the strong airway stimulation and psychological fear of patients. To improve these, the method of general anesthesia with laryngeal mask airway (LMA)-assisted ventilation is recently developed, which retains spontaneous breathing. This technique is advantageous in painless flexible bronchoscopy due to its safety, effectiveness, and ease of use . Dreaming is a subjective experience which is produced both physically and psychologically during physical sleeping . Although there are essential differences between anesthesia and sleeping, dreaming during anesthesia is common and is considered to be a different experience from anesthesia induction to awakening (except for intraoperative awareness). Dreams can be produced not only during long-duration surgery under general anesthesia, but also in brief surgeries, which are associated with a higher incidence rate of dreaming [4,5]. In addition, recent research has suggested that dreaming during general anesthesia has no effect on satisfaction of patients with the procedure. Dreaming under anesthesia, which is distinct from intraoperative awareness, is considered as a high-risk factor for awareness . Light anesthesia is a major cause of dreaming and intraoperative awareness. Midazolam is a short-acting benzodiazepine hypnotic-sedative drug that can enhance the inhibition and blocking of cortical and limbic arousal by stimulating the inhibitory transmitter g-aminobutyric acid (GABA) receptor in ascending reticular activating system. Consequently, midazolam produces favorable sedative and anterograde amnesia effects. Accumulating studies have shown that midazolam is one of the most widely used sedatives during bronchoscopy due to its anxiolytic and amnesic properties, as well as favorable pharmacokinetic characteristics such as rapid-onset and short-lasting inhibitory effects on the central nervous system. Moreover, it can be rapidly counteracted by flumazenil, a competitive antagonist for the benzodiazepine receptors, which enables rapid awakening and recovery of patients undergoing flexible bronchoscopy . Dexmedetomidine is a new type of highly selective adrenoceptor agonist with sedative, amnestic, sympatholytic, and analgesic properties, which has been demonstrated to be effective for painless flexible bronchoscopy . To date, no comparative studies have reported the effects of these 2 drugs on dreaming of patients undergoing flexible bronchoscopy during general anesthesia. The present study compared the effects of dexmedetomidine and midazolam on dreaming of patients undergoing flexible bronchoscopy during general anesthesia and assessed the incidence and characteristics of dreams, as well as the degree of sedation. Our results may provide a reference for satisfactory medical treatment using similar procedures in the future.
Material and Methods
This study was approved by the Institutional Review Board of the Hefei Affiliated Hospital of Anhui Medical University (IRB-approved registration number 20190711). Written informed consent from each patient was obtained before the study. A total of 80 patients posted from American Society of Anesthesiologists Grades I and II with flexible bronchoscopy under general anesthesia between March 2019 and June 2020 were reviewed, including 43 males and 37 females, aged 37~71 years old, and weighing of 47~84 kg. Inclusion criteria were: (1) undergoing flexible bronchoscopy under general anesthesia; (2) without language, mental, or comprehension impairment, and can communicate normally; (3) without history of neuropsychiatric disorders, drug dependence, and alcohol abuse; (4) without serious cardiovascular and cerebrovascular diseases, or major organ dysfunction preoperatively; (5) aged 18 to 75 years old; (6) sign the informed consent form. Exclusion criteria were: (1) history of known allergy to dexmedetomidine or midazolam; (2) language, mental, or comprehension impairment and inability to communicate normally; (3) history of neuropsychiatric disorders, drug dependence, or alcohol abuse; (4) serious cardiovascular and cerebrovascular diseases, or major organ dysfunction preoperatively; (5) older than 75 years old or younger than 18 years old; (6) participating in other clinical trials. All patients were randomly divided into either the dexmedetomidine group (Group D,
All patients were instructed not to eat for 8 hours or to drink for 4 hours prior to procedures and no preoperative drugs were administered. Routine monitoring devices were set up to monitor electrocardiogram, heart rate (HR), noninvasive blood pressure (BP), oxygen saturation (SpO2), respiratory rate (RR), partial pressure of end-tidal carbon dioxide (PetCO2), and bispectral (BIS) index of patients. O2 at 2 L/min was applied through a nasal catheter and intravenous access was opened. All patients were atomized to inhale 5 ml 1% lidocaine before procedures. In group D, patients received 0.5 μg/kg dexmedetomidine and in group M patients received 0.05 mg/kg midazolam intravenously over a 10-min period before general anesthesia induction. Intravenous injection of fentanyl (1 μg/kg) and propofol (2.5 mg/kg) were given during induction. After emergence of consciousness, an i-gel laryngeal mask airway (manufactured by Intersurgical UK) was intubated. Vital signs, RR, and tidal volume were observed closely. In the case of weak breath, SpO2 decrease, VT decrease, RR decrease, or apnea, the oxygen inhalation flow rate was increased, the ventilation mode of anesthesia machine was adjusted to synchronous intermittent instruction ventilation (SIMV) and intermittent positive pressure ventilation (IPPV), and VT, RR, and other parameters were modified accordingly. As the condition of patients stabilized, a fully lubricated bronchoscope was inserted into the glottis via swivel connector, which was connected to the i-gel and anesthesia equipment. Subsequently the procedure started and propofol was continuously infused at the rate of 5~7 mg/kg/h. Subsequently, 2% lidocaine solution 1 ml was applied via the suction channel of a flexible bronchoscope to avoid severe airway response during the procedure. The procedure was suspended if SpO2 dropped below 90%. Patients were transferred to the recovery room after bronchoscopy. I-gel was extubated after the recovery of patient orientation to time and place.
We collected data on demographic characteristics (sex, age, weight, height, history of smoking) and usual condition of dreaming (0=never; 1=once a month; 2=once a week; 3=almost every day).
We collected data on drug dose (propofol), duration of anesthesia (time between the induction and the end of anesthesia), duration of operation (time between the beginning and the end of anesthesia), and i-gel extubation time (time between withdrawal of drugs at the end of operation and i-gel extubation). The index of BIS at the time of entry (T0), after induction and at the beginning of surgery (T1), immediately after surgery (T2), and i-gel extubation (T3) were recorded.
POSTOPERATIVE DATA: The key points of evaluation were: Orientation recovery time (time between withdrawal of drugs and orientation of patients to time, place, and person) and Ramsay score during orientation recovery (Ramsay sedation scale: 1=patient anxious, agitated or restless or both; 2=patient cooperative, oriented, tranquil, and alert; 3=patient responds to commands; 4=asleep, but with brisk response to light glabellar tap or loud auditory stimulus; 5=asleep, sluggish response to light glabellar tap or loud auditory stimulus; 6=asleep, shows no response to light glabellar tap or loud auditory stimulus) . The comfort level of patients after surgery was assessed by VAS score (0=highest possible dissatisfaction, 100=highest possible satisfaction).
TIME AND METHOD OF DREAMING INVESTIGATION:
After emergence from sedation and orientation recovery, a modified Brice questionnaire was immediately used to evaluate the incidence of dreaming. Patients who reported dreaming were required to complete a 5-point Likert scale survey regarding the contents of their dreams.
Modified Brice questionnaire :
The 5-Point Likert Scale :
STATISTICAL ANALYSIS: According to previous research data , using PASS 15.0 software (NCSS, LLC, Kaysville, USA), and based on 80% power and a 5% margin of error, the total sample size needed was calculated to be 79 (39 in group D and 40 in group M). A total of 80 participants were finally included, with 40 in each group.
Statistical analysis of the data collected was performed using SPSS software package (version 24.0; IBM Corporation, Armonk, NY). The independent-samples
We included 84 patients in this study. One patient refused to participate and three patients did not meet inclusion criteria. The remaining 80 patients completed the study. The flowchart is summarized in Figure 1. Table 1 summarized the comparison between group D and M. There were no significant differences between 2 groups in sex, age, weight, height, history of smoking, drug dose, duration of operation and anesthesia, i-gel extubation time, and usual condition of dreaming.
There was also no significant difference between the 2 groups in the BIS index at different times (Table 2).
Interestingly, compared to group M, patients in group D had higher Ramsay scores and VAS scores, and the differences were statistically significant (P<0.05) (Table 3).
Dreaming frequency was statistically different (P<0.05) between groups (Table 4), with group D reporting more dreaming (17.5%) than group M (37.5%).
In the final analysis, the characteristics of recallable dreams were further examined and summarized in Table 5. Most of the dreams recalled by patients in both groups were pleasant. Compared to group M, the memorability of dreams in group D was lower (P<0.05), while no significant difference was found in terms of emotion, voice, and movement scores of dreams. During the bronchoscopy procedure and recovery period, there was no significant difference in blood pressure, blood oxygen saturation, or heart rate between group M and group D (P>0.05).
Although bronchoscopy is a minimally invasive procedure, it inevitably introduces strong irritants to patients, which leads to severe coughing and strong fluctuations in hemodynamics during the procedure. In addition to psychological fear, it is potentially life-threatening to patients. To address these problems, painless flexible bronchoscopy has been developed and widely applied. In this study, after anesthesia induction i-gel was intubated, which can guarantee ventilation, and then the operation was started. Notably, the i-gel airway is a novel supraglottic airway device with a unique non-inflatable cuff made of thermoplastic elastomer. The gel-like cuff accurately mirrors perilaryngeal anatomy to create a perfect fit . Overall, the methods were used to minimize the risk during the procedure and ensure patients’ safety.
Dreaming during anesthesia is defined as any experiences and thoughts that occur between anesthesia induction and the time of awakening. During physiological sleep, most dreams that people can recall after awakening occur during the stage of rapid eye movement sleep. The occurrence of dream during anesthesia is affected by several factors, such as race, sex, depth of anesthesia, length of anesthesia time, and anesthetic drugs. In this study, the comparison between dexmedetomidine and midazolam was examined, with no significant differences in sex, age, weight, height, history of smoking, usual condition of dreaming, dosage of drugs, operation and anesthesia time, i-gel extubation time, and orientation recovery time of patients between the 2 groups. The BIS index was maintained at the same level during anesthesia. Overall, the indicators mentioned above had no effect on the results. The Brice questionnaire and 5-point Likert scale are widely used in clinically evaluating dreams, and these were used in the present study. Our results demonstrated that the frequency of dreaming in group D (17.5%) was lower than that in group M (37.5%), which suggests that dexmedetomidine reduces the incidence of dreaming during general anesthesia when compared to midazolam. Dexmedetomidine is an a2 adrenergic agonist that exhibits various advantages over traditional benzodiazepines drugs, including weak respiratory inhibition and weak mucosal stimulation. a2 adrenergic agonists are abundant in the locus ceruleus and nucleus pulposus in the brainstem and are closely related to anxiety, sleep-wake, and withdrawal of antianxiety drugs . The locus ceruleus and dorsal raphe nuclei play critical roles in regulation of sleep. Upon sedation by dexmedetomidine, the locus ceruleus is inhibited, and ventrolateral preoptic area activity is elevated, which is similar to the stage of non-rapid eye movement .
Previous studied have revealed that light anesthesia may be one of the contributing factors for occurrence of dreaming . In the present study, Ramsay scores in group D were higher than that of group M when orientation was restored, indicating that the level of sedation in group D was deeper; therefore, the incidence of dreaming was lower in group M. More importantly, most of the recallable dreams reported in this study were pleasant. Compared to group M, group D had less voice and motion in dreams, as well as a significantly lower memorability of dreams. These phenomena are potentially related to the depth of sedation (Ramsay score), as supported by previous studies . The satisfaction of patients in group D was notably higher than in group M, which could be attributed to the effects of dexmedetomidine on sedation, analgesia, and antianxiety and decrease of airway reactivity . Moreover, we found that the vital signs (eg, blood pressure, heart rate, and blood oxygen saturation) of the 2 groups were at the ideal levels, and there was no statistically significant difference during the bronchoscopy procedure and recovery period, indicating the safety of these 2 drugs.
However, there are several limitations in the study. First, no study was performed on the long-term effects after bronchoscopy. Moreover, variation in occurrence and contents of dreams during anesthesia was found in patients with different cultural backgrounds, religious beliefs, and living environments. In addition, the description and memorability of dreams by patients were subjective. During the interview, recall and narration from dreamers might not necessarily accurately represent their actual dreams. In addition, limitations also exist in the methods used. To address these issues, in future studies we will compare the results of groups of patients with different sex ratios and levels of education. Furthermore, we will improve the objectivity of our results by use of more advanced equipment, such as electroencephalogram and auditory evoked potential equipment. Long-term follow-up studies after surgery are needed to continue the investigation of the condition and content of dreaming in patients undergoing flexible bronchoscopy. Undoubtedly, the present study and future research on the factors influencing dreaming under anesthesia will provide valuable insights into this phenomenon.
In summary, compared to midazolam, pre-injection of dexmedetomidine before anesthesia induction significantly decreased the incidence of dreaming in patients undergoing flexible bronchoscopy. Although they both produced no effect on the content of dreams (most of them were pleasant), dexmedetomidine decreased the incidence of agitation. Overall, it provides more effective sedation during recovery and improves patient comfort and satisfaction.
TablesTable 1. Comparison of demographic information, clinical data of patients in the 2 groups (n=40, both). Table 2. Comparison of BIS index of patients in the 2 groups (n=40 each). Table 3. Ramsay score and VAS score of patients in the 2 groups (n=40 each). Table 4. Incidence of dreaming of patients in the 2 groups (n=40 each). Table 5. Comparison of Likert score of the 2 groups (M(Q)).
1. José RJ, Shaefi S, Navani N: Sedation for flexible bronchoscopy: Crrent and emerging evidence: Eur Respir Rev, 2013; 22(128); 106-16
2. Suzen A, Karakus SC, Erturk N: The role of flexible bronchoscopy accomplished through a laryngeal mask airway in the treatment of tracheobronchial foreign bodies in children: Int J Pediatr Otorhinolaryngol, 2019; 117; 194-97
3. Schredl M, Wittmann L, Ciric P, Götz S: Factors of home dream recall: A structural equation model: J Sleep Res, 2003; 12(2); 133-41
4. Hellwagner K, Holzer A, Gustorff B: Influence on patient anxiety and satisfaction: Eur J Anaesthesiol, 2003; 20(4); 282-88
5. Leslie K, Skrzypek H, Paech MJ: Dreaming during anesthesia and anesthetic depth in elective surgery patients: A prospective cohort study: Anesthesiology, 2007; 106(1); 33-42
6. Huang GH, Davidson AJ, Stargatt R: Dreaming during anaesthesia in children: Incidence, nature and associations: Anaesthesia, 2005; 60(9); 854-61
7. Goneppanavar U, Magazine R, Periyadka Janardhana B, Krishna Achar S: Intravenous dexmedetomidine provides superior patient comfort and tolerance compared to intravenous midazolam in patients undergoing flexible bronchoscopy: Pulm Med, 2015; 2015; 727530
8. Sinha SK, Joshiraj B, Chaudhary L: A comparison of dexmedetomidine plus ketamine combination with dexmedetomidine alone for awake fiberoptic nasotracheal intubation: A randomized controlled study: J Anaesthesiol Clin Pharmacol, 2014; 30(4); 514-19
9. Ramsay MA, Savege TM, Simpson BR, Goodwin R: Controlled sedation with alphaxalone-alphadolone: Br Med J, 1974; 2(5920); 656-59
10. Moonesinghe SR, Walker EM, Bell M: Design and methodology of SNAP-1: A Sprint National Anaesthesia Project to measure patient reported outcome after anaesthesia: Perioper Med (Lond), 2015; 4; 4
11. Tezcan AH, Ornek DH, Ozlu O: Abuse potential assessment of propofol by its subjective effects after sedation: Pak J Med Sci, 2014; 30(6); 1247-52
12. Bamgbade OA, Macnab WR, Khalaf WM: Evaluation of the i-gel airway in 300 patients: Eur J Anaesthesiol, 2008; 25(10); 865-66
13. Gupta S, Singh D, Sood D, Kathuria S: Role of dexmedetomidine in early extubation of the intensive care unit patients: J Anaesthesiol Clin Pharmacol, 2015; 31(1); 92-98
14. Yu SB: Dexmedetomidine sedation in ICU: Korean J Anesthesiol, 2012; 62(5); 405-11
15. Xu GH, Liu XS, Yu FQ: A randomised controlled trial: Anaesth Intensive Care, 2012; 40(3); 505-10
16. Chen JY, Jia JE, Liu TJ: Comparison of the effects of dexmedetomidine, ketamine, and placebo on emergence agitation after strabismus surgery in children: Can J Anaesth, 2013; 60(4); 385-92
22 September 2021 : EditorialEditorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic M...
Med Sci Monit In Press; DOI: 10.12659/MSM.934854
08 September 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit In Press; DOI: 10.12659/MSM.932788
16 July 2021 : Review articleSilent Hypoxemia in Patients with COVID-19 Pneumonia: A Review
Med Sci Monit In Press; DOI: 10.12659/MSM.930776
22 Sep 2021 : EditorialEditorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic M...
Med Sci Monit In Press; DOI: 10.12659/MSM.934854
22 Sep 2021 : Clinical ResearchA Comparative Study of the Clinical Efficacy and Safety of Pneumatic Trabeculoplasty and Selective Laser Tr...
Med Sci Monit In Press; DOI: 10.12659/MSM.933454
20 Sep 2021 : Clinical ResearchComparison of the Use of Magnetic Resonance Imaging of Partial Anterior Cruciate Ligament Tears Using Maxim...
Med Sci Monit In Press; DOI: 10.12659/MSM.932228
20 Mar 2020 : Clinical ResearchSocial Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...
Med Sci Monit 2020; 26:e923921
15 Apr 2020 : Clinical ResearchPsychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...
Med Sci Monit 2020; 26:e924171
05 May 2020 : Review articleAn Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Med Sci Monit 2020; 26:e924700